
Poseida Therapeutics: New Allogeneic Therapies, Leveraging Non-Viral Engineering (PSTX)
metamorworks Poseida Therapeutics, Inc. (NASDAQ:PSTX) reported Q3 2022 revenues of $116.31 million beating Wall Street estimates by $115.47 million- a stretch of almost 100%. The clinical-stage cell and gene therapy company’s EPS in the quarter […]